Fernando J Barreyro

Family First, MD, PhD Gastroenterology & Hepatology, Associate Researcher, National Scientific and Technical Research Council (CONICET). Head, Liver Unit, IOT

[Rohit Loomba @DrLoomba]

So proud of you Harris- keep it up! @aichemzee @MASLDResearch @mashtagconf

[Elliot Tapper @ebtapper]

An RCT of ROTEM before procedures in cirrhosis

Key points
1. Congratulations to Dr Janko!
2. Less FFP, more cryo - as expected

I will add:
1. Tired: ROTEM as a stewardship tool
2. Wired: just say no to HARMFUL transfusions

[Antelm Pujol, MD PhD @AntelmPujol]

😴 Dormir 90 minutos menos cada noche durante solo 6 semanas provocó:

📈 +0,45 kg de peso
📏 +0,52 cm de cintura
🪑 +17 min/día más de sedentarismo

La calidad del sueño debería formar parte de cualquier estrategia para perder peso.

[EndoCollab™ | GI Endoscopy Community @EndoCollabcom]

Chromoendoscopy is more than spraying blue dye and hoping. Know the agent class, concentration, application route, and what optical system you will use next.

1/ Dye classes differ. Contrast agents like indigo carmine vs absorptive agents like methylene blue and crystal violet.

2/ Indigo carmine in practice. Indigo carmine helps detection and surface characterization, and concentration plus delivery route change the job.

3/ Detection gain. Pancolonic indigo carmine chromoendoscopy improved neoplastic lesion detection versus standard colonoscopy in a randomized trial.

4/ NICE optical classification. After dye or NBI, optical systems such as NICE help translate color, vessels, and surface pattern into likely pathology.

[EndoCollab™ | GI Endoscopy Community @EndoCollabcom]

Should you clip after polypectomy? A 5,380-patient analysis says yes for right-sided polyps (OR 0.62).

But the real skill gap is submucosal injection. This 5-min clip shows injection done wrong vs the dynamic technique.

https://t.co/Vj15uTFlZm

[Scott Isaacs @scottisaacsmd]

Vitamin E dosing study in patients with #MASLD.
https://t.co/w1gPJEqWHX

[NEJM @NEJM]

𝗖𝘂𝗿𝗿𝗲𝗻𝘁 𝗮𝗻𝗱 𝗙𝘂𝘁𝘂𝗿𝗲 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗕𝗮𝗿𝗿𝗲𝘁𝘁’𝘀 𝗘𝘀𝗼𝗽𝗵𝗮𝗴𝘂𝘀

Panel A shows the current approach to managing Barrett’s esophagus. The disease is diagnosed on a case-by-case basis, with patients entering a vicious circle of lifetime endoscopy checkups and treatment if dysplasia or early cancer is detected. Patients exit the circle if they become too frail for further checkups, have a missed cancer (i.e., an interval cancer diagnosed before the next cycle of surveillance) warranting systemic treatment, or die from another cause. Panel B shows a future risk-based, population-control approach to managing Barrett’s esophagus. The population to be offered screening is enriched on the basis of risk factors. A triage test determines whether the patients in this population have a low, average, or high lifetime risk of cancer. The approach to management is tailored to each patient to minimize harm and maximize detection of dysplasia or stage I cancer.

Learn more about the management of Barrett’s esophagus in a new Clinical Practice article by Rebecca C. Fitzgerald, MD (@RFitzgerald_lab), from the University of Cambridge (@cambridge_uni): https://t.co/DEfidqHRVI

[The Lancet @TheLancet]

Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new treatments.

A new study found that GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity: https://t.co/MhUTBf9G7h

[Scott Isaacs @scottisaacsmd]

This NEJM Perspective highlights a growing problem with GLP-1 therapy: rising off-label, lifestyle use, little eating-disorder screening, and millions at risk of silent harm if we do not build safeguards now.
https://t.co/2qfJTwZM5Q

[Elliot Tapper @ebtapper]

Every month I record a little video on the papers coming out in @HepCommJournal and I get so pumped

See for yourself https://t.co/nrN6MDwBc9

Reviews on FMT, HCC screening, and the GESA Portal htn consensus. Second-line AIH treatment. MASH recompensation. HRS mgmt...

[Elliot Tapper @ebtapper]

What if Ferritin applied for a job?

[Gastroenterology @AGA_Gastro]

Phosphatidylethanol (PEth) predicts hepatic decompensation independently of NITs in those at risk of alcohol-related liver disease. Repeated PEth sustains prognostic utility.
🔗 https://t.co/0deS5ZFtuR
@NikolajTorp @AleksanderKrag @IsraelsenMads @MajaThiele

[CGH @AGA_CGH]

🧬 Who should be treated for MASLD? This Hepatology original research article explores a practical criteria set—combining FIB‑4, transient elastography, diabetes, and overweight status—to better guide treatment decisions. 📖✨

Read More: https://t.co/izzSVcv3WT

[Elliot Tapper @ebtapper]

A must read by THE P.P. Bloom

The past, present, and future of 💩 transplant in liver disease

https://t.co/CJuoRVENVY @BloomPringle @HepCommJournal @MayoClinicGIHep

[Scott Isaacs @scottisaacsmd]

New @AmerGastroAssn MASLD pathway: for people with type 2 diabetes, you can now skip FIB-4 and go straight to elastography when it’s available.
https://t.co/gb7Mymtotf

[Elliot Tapper @ebtapper]

What’s the utilization of AI devices for endoscopy, say, a year after installing them?

[CGH @AGA_CGH]

🛎️"Dynamic FIB-4 changes are linked to liver fibrosis progression and adverse outcomes in MASLD. Regular monitoring may support early risk detection and management."

🔗: https://t.co/dNyIb8yd6T

[CardioTeca @cardioteca]

🔎 Tirzepatide vs semaglutide: menor riesgo cardiovascular estimado a 10 años en obesidad

Lee el artículo completo: https://t.co/ytseD22OGx

❤️ Menor riesgo a 10 años estimado tras 72 semanas con tirzepatide que con semaglutide.
⚖️ La diferencia aparece pronto (desde la semana 12) y se mantiene a lo largo del seguimiento.
📉 Se acompaña de mayores descensos en IMC y presión arterial sistólica con tirzepatide.
🌍 Al extrapolar a población elegible, se estiman más eventos cardiovasculares potencialmente evitables con tirzepatide.

[Elliot Tapper @ebtapper]

When used wisely albumin can help patients with cirrhosis says the best meta-analysis on this in @HepCommJournal

https://t.co/wKMh5zoXHw

But these trials are small and misuse - SO COMMON - outside of trials is harmful. How to thread the needle?

[Nature Reviews Gastroenterology & Hepatology @NatRevGastroHep]

New online! Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management https://t.co/XdWDDLUXwp